Member Info for BuenaVista

Would love an RNS saying the board had received and rejected an unsolicited offer for the company. That would really fire the starting gun.

I know it's a conplete waste of time so I voted YES!!!!! Sorry NO, absolutely not. A hypothetical 800p? Pfft!

I'd not seen that before. Thanks.

Other priorities is another possibility. The leads seem to becoming from er... Leeds.

Da Dum... Tish!

I'll get my coat

All is not lost Cheesey as the remaining patent life for Affimers is long enough to discover commercially exploitable uses that will have their own 20 year patent protection. Also, pre|CISION seems destined to account for most of the SP for the foreseeable. However, if someone can reason why Affimers are set left on the starting block, I'm all ears.

I can't help feeling that, for all their projected promise, Affimers are being underexploited commercially. Today Aptamer announced 2 agreements for their Optimers "initially worth over £500,000, subject to the successful progression of Optimer development, with the potential for downstream milestone and royalty/licensing payments". These were described as 'substantial' but that is relative as the Aptamer MCap is only £27m or so. Despite that small MCap, Aptamer have many more partners than Avacta for this technology, including AstraZeneca, Cancer Research UK and even Takeda. And Deepverge of course.
https://aptamergroup.com/portfolio/

If Affimers are so specific for this and that target, where are the licence agreements? If baffles me.

Terry's over at KOD getting spiked

Get this:

Phase II studies

Doctors use the information gathered in a Phase I study to help decide:
- the dose of treatment
- the frequency of treatment
- the particular cancers which may respond best to the treatment.

Several Phase II trials will be carried out on different cancers so that doctors can find out how active a particular drug is. Only about 20 to 30 patients with each cancer are needed to take part in this early work for each tumour type. They will be watched very carefully for the effects and side effects of treatment using regular check-ups, blood tests, x-rays or scans. If the drug doesn’t work, no more trials will be carried out. However, if a significant number of responses are seen, the doctors will design a Phase III study.

Phase III studies

A Phase III study will try to compare a new treatment with the best treatment currently available and the following are monitored:
- the effect of the treatment on the cancer
- how long the effects last
- the side effects of the treatment
- any possible longer-term problems which could develop.

If the differences between the new treatment and the existing treatment are small, hundreds of patients may need to take part before one is identified as better than the other. Studies may take place in several different hospitals at the same time, including hospitals in other countries.

Phase III trials are usually randomised and may include a double-blind procedure. Find out more about organising clinical trials.
https://www.royalmarsden.nhs.uk/about-royal-marsden/our-research/clinical-trials/what-types-clinical-trial-are-there

-----------------------

How could a Phase III study possibly be organised when the standard treatment (doxorubicin or any of the other anthracyclines) causes obvious side effects whilst AVA6000 doesn't and its efficacy will have already been proven in Phase II? A complete nonsense given that the efficacy of straight doxorubicin is so well known; no need to do a live comparison study, just look at the data in doxorubicin trial reports!

£3 or £30?

Systemzero needs to know because he'll be selling at £3.

How did you arrive at £10 per share?
Please show your workings.
;0)

Did you ask for 100 word paragraphs PL?

I'll lay a place for ChatGPT at the next dinner party. He can keep the guests entertained whilst the burnt joint is being recovered.

Geopolitical consequences of Russia's Special Military Embarrassment in Ukraine anyone?

Sorry, I can't see that. I have you on filter.

What do the charts say the shareprice will move to when the dose escalation RNS is released?

Looking for contracts?

Looking for contracts?

I don't think it far fetched JT. Being all their FDA ducks lined up before progressing to Phase 1b makes sense.
Also, note that the FDA will grant funds for ODD trials outside the US and whilst carrying out trials in the US has that certain 'invented here' air about it, the focus on AVA6000 by the time the trial results come through may be such that it wouldn't matter where the trials were carried out.

I'm crying a river for you

But would you be disapointed if it didn't?

There's nothing there to indicate 'a little limelight of its own soon'.

However, if you want to create a false deadline that you can then decry when it's not met, then go ahead - we'll all know what you are.

Ceri, I don't know the answer. I've never studied or practiced pharmacology or biochemistry or any of the life sciences.

What I do know though is that if you were doing research back in 1969, then you must be well past retirement age by now and your son in his late 30s or into his 40s, at least. If he got an MSc in Biochemistry then he's unlikely to have been much more than 23 at the time.

Also that the life sciences advance so rapidly that anything over 5 years old is already out of date and has been replaced by new understandings. Thus, I wouldn't place too much weight on your son's out-of-date knowledge.